Modus Therapeutics Holding AB (publ) (MODTX.ST) Research
Founded in 2011 and headquartered in Stockholm, Sweden, Modus Therapeutics Holding AB (publ) is a biotechnology firm dedicated to developing treatments for sepsis and septic shock. Its primary product, Sevuparin, a polysaccharide, is presently undergoing Phase Ib clinical evaluation for its potential in treating patients afflicted with these serious conditions.
Market snapshot
- Symbol
- MODTX.ST
- Price
- $0.40
- Day change
- -0.49%
- Market cap
- $36.8M
- P/E ratio
- -1.88x
- 52-week range
- 0.208-5
- Sector
- Healthcare
- Industry
- Biotechnology
Peer companies
- 2cureX AB (publ) (2CUREX.ST)
- Aino Health AB (publ) (AINO.ST)
- Episurf Medical AB (publ) (EPIS-B.ST)
- ExpreS2ion Biotech Holding AB (publ) (EXPRS2.ST)
- Fluicell AB (publ) (FLUI.ST)
- Guard Therapeutics International AB (publ) (GUARD.ST)
- Lipigon Pharmaceuticals AB (publ) (LPGO.ST)
- Qlife Holding AB (publ) (QLIFE.ST)
Open Modus Therapeutics Holding AB (publ) (MODTX.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.